These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11499810)

  • 1. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial.
    Bear HD; Roberts J; Cornell D; Tombes MB; Kyle B
    Cancer Immunol Immunother; 2001 Jul; 50(5):269-74. PubMed ID: 11499810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
    Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
    Parviz M; Chin CS; Graham LJ; Miller C; Lee C; George K; Bear HD
    Cancer Immunol Immunother; 2003 Dec; 52(12):739-50. PubMed ID: 12827306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases.
    Tuttle TM; Inge TH; Lind DS; Bear HD
    Surg Oncol; 1992 Aug; 1(4):299-307. PubMed ID: 1341264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients.
    Lind DS; Tuttle TM; Bethke KP; Frank JL; McCrady CW; Bear HD
    Surg Oncol; 1993 Oct; 2(5):273-82. PubMed ID: 8305969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bryostatin 1 activates T cells that have antitumor activity.
    Tuttle TM; Inge TH; Wirt CP; Frank JL; McCrady CM; Bear HD
    J Immunother (1991); 1992 Aug; 12(2):75-81. PubMed ID: 1504056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
    J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro.
    Fleming MD; Bear HD; Lipshy K; Kostuchenko PJ; Portocarero D; McFadden AW; Barrett SK
    J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):147-55. PubMed ID: 8770770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
    Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
    Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
    Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro.
    Haynes C; Graham L; Bear HD
    Methods Cell Biol; 2024; 183():355-380. PubMed ID: 38548419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. gamma-Interferon plays a key role in T-cell-induced tumor regression.
    Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
    Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.
    Baldwin NG; Rice CD; Tuttle TM; Bear HD; Hirsch JI; Merchant RE
    J Neurooncol; 1997 Mar; 32(1):19-28. PubMed ID: 9049859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bryostatin 1-activated T cells can traffic and mediate tumor regression.
    Tuttle TM; Bethke KP; Inge TH; McCrady CW; Pettit GR; Bear HD
    J Surg Res; 1992 Jun; 52(6):543-8. PubMed ID: 1528028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression.
    Tuttle TM; Fleming MD; Hogg PS; Inge TH; Bear HD
    Ann Surg Oncol; 1994 Jan; 1(1):53-8. PubMed ID: 7834429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.
    Cha E; Graham L; Manjili MH; Bear HD
    Breast Cancer Res Treat; 2010 Jul; 122(2):359-69. PubMed ID: 19826947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precursor frequency analysis of bryostatin activated lymphocytes.
    Fleming MD; Barrett SK; Bear HD
    J Surg Res; 1994 Jul; 57(1):74-9. PubMed ID: 8041153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of CD8+ murine T cells from tumor-draining lymph nodes by phorbol dibutyrate plus calcium ionophore.
    Tuttle TM; Inge TH; McCrady CM; Bethke KP; Bear HD
    J Immunother (1991); 1992 Jul; 12(1):32-40. PubMed ID: 1386251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
    Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
    J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.